Antifungal agents--clinical pharmacokinetics and drug interactions (Q37159568)

18 August 2017

1 reference

title

Antifungal agents--clinical pharmacokinetics and drug interactions (English)

1 reference

18 August 2017

1 reference

1

Hans-Peter Lipp

1 reference

18 August 2017

1 January 2008

1 reference

18 August 2017

1 reference

18 August 2017

51 Suppl 1

1 reference

18 August 2017

7-18

1 reference

Risk factors for amphotericin B-induced nephrotoxicity

18 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Differences in pharmacokinetics of amphotericin B lipid formulations despite clinical equivalence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Micafungin: a new echinocandin antifungal

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Potential for interactions between caspofungin and nelfinavir or rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Safety and pharmacokinetics of coadministered voriconazole and anidulafungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Voriconazole: a new triazole antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Drug metabolism and variability among patients in drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Blood concentrations of everolimus are markedly increased by ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Making sense of itraconazole pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Pharmacokinetics of intravenous itraconazole in stable hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Update on drug interactions with azole antifungal agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Pharmacokinetic/pharmacodynamic profile of voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Adverse reactions to voriconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Successful use of voriconazole for treatment of Coccidioides meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Identification of the Cytochrome P450 Enzymes Involved in theN-Oxidation of Voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Posaconazole: clinical pharmacology and potential for management of fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Disposition of posaconazole following single-dose oral administration in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Activity of posaconazole in the treatment of central nervous system fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Primary antifungal prophylaxis in leukaemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

Potent cytochrome P450 2C19 genotype–related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2008.01523.X

10.1111/J.1439-0507.2008.01523.X

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18471156